Adverum Biotechnologies, Inc.

This study follows 23 people who received a single dose of ADVM-022 gene therapy for wet age-related macular degeneration (AMD) in an earlier trial. Researchers are monitoring long-term safety and how well the treatment controls vision loss and retinal swelling over time. The goa…